The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B
Abstract
Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis B patients under long‐term therapy with potent nucleos(t)ide analogues is currently unclear. We therefore assessed the HCC incidence beyond year 5 of entecavir/tenofovir (ETV/TDF) therapy and tried to determine possible factors associated with late HCC occurrence. This European, 10‐center, cohort study included 1,951 adult Caucasian chronic hepatitis B patients without HCC at baseline who received ETV/TDF for ≥1 year. Of them, 1,205 (62%) patients without HCC within the first 5 years of therapy have been followed for 5‐10 (median, 6.8) years. HCCs have been diagnosed in 101/1,951 (5.2%) patients within the first 5 years and 17/1,205 (1.4%) patients within 5‐10 years. The yearly HCC incidence rate was 1.22% within and 0.73% after the first 5 years (P = 0.050). The yearly HCC incidence rate did not differ within and after the first 5 years in patients without cirrhosis (0.49% versus 0.47%, P = 0.931), but it significantly declined in patients with cirrhosis (3.22% versus 1.57%, P = 0.039). All HCCs beyond year 5 developed in patients older than 50 years at ETV/TDF onset. Older age, lower platelets at baseline and year 5, and liver stiffness ≥12 kPa at year 5 were independently associated with more frequent HCC development beyond year 5 in multivariable analysis. No patient with low Platelets, Age, Gender‐Hepatitis B score at baseline or year 5 developed HCC. Conclusion: The HCC risk decreases beyond year 5 of ETV/TDF therapy in Caucasian chronic hepatitis B patients, particularly in those with compensated cirrhosis; older age (especially ≥50 years), lower platelets, and liver stiffness ≥12 kPa at year 5 represent the main risk factors for late HCC development. (H epatology 2017;66:1444–1453).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Sampling Variability of Liver Fibrosis in Chronic Hepatitis C
Bedossa, P., Dargère, D., & Paradis, V. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.022 · Cited by 2,376
Bravo, A. A., Sheth, S. G., & Chopra, S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440706 · Cited by 2,041
AASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Self-citationMechanisms of HBV-induced hepatocellular carcinoma
Levrero, M., & Zucman-Rossi, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.021 · Cited by 1,052
Hosaka, T., Suzuki, F., Kobayashi, M., Seko, Y., Kawamura, Y., Sezaki, H., Akuta, N., Suzuki, Y., Saitoh, S., Arase, Y., et al. (2013) · Hepatology · doi:10.1002/hep.26180 · Cited by 710
Tsochatzis, E. A., Gurusamy, K. S., Ntaoula, S., Cholongitas, E., Davidson, B. R., & Burroughs, A. K. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.033 · Cited by 709
Yang, H.-I., Yuen, M.-F., Chan, H. L.-Y., Han, K.-H., Chen, P.-J., Kim, D.-Y., Ahn, S.-H., Chen, C.-J., Wong, V. W.-S., & Seto, W.-K. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70077-8 · Cited by 669
Yuen, M.-F., Tanaka, Y., Fong, D. Y.-T., Fung, J., Wong, D. K.-H., Yuen, J. C.-H., But, D. Y.-K., Chan, A. O.-O., Wong, B. C.-Y., Mizokami, M., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.023 · Cited by 584
Papatheodoridis, G., Dalekos, G., Sypsa, V., Yurdaydin, C., Buti, M., Goulis, J., Calleja, J. L., Chi, H., Manolakopoulos, S., Mangia, G., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.035 · Cited by 557
Self-citationPapatheodoridis, G. V., Chan, H. L.-Y., Hansen, B. E., Janssen, H. L. A., & Lampertico, P. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.002 · Cited by 511
Self-citationClinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers
Wong, V. W.-S., Chan, S. L., Mo, F., Chan, T.-C., Loong, H. H.-F., Wong, G. L.-H., Lui, Y. Y.-N., Chan, A. T.-C., Sung, J. J.-Y., Yeo, W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2675 · Cited by 502
Papatheodoridis, G. V., Lampertico, P., Manolakopoulos, S., & Lok, A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.035 · Cited by 459
Self-citationSu, T., Hu, T., Chen, C., Huang, Y., Chuang, W., Lin, C., Wang, C., Su, W., Chen, M., Peng, C., et al. (2016) · Liver International · doi:10.1111/liv.13253 · Cited by 223
Kim, W. R., Loomba, R., Berg, T., Aguilar Schall, R. E., Yee, L. J., Dinh, P. V., Flaherty, J. F., Martins, E. B., Therneau, T. M., Jacobson, I., et al. (2015) · Cancer · doi:10.1002/cncr.29537 · Cited by 212
Self-citationTherapeutic strategies in the management of patients with chronic hepatitis B virus infection
Papatheodoridis, G. V., Manolakopoulos, S., Dusheiko, G., & Archimandritis, A. J. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70264-5 · Cited by 202
Self-citationRisk Stratification and Therapeutic Decision Making in Acute Coronary Syndromes
Ohman, E. M. (2000) · JAMA · doi:10.1001/jama.284.7.876 · Cited by 193
Papatheodoridis, G. V., Manolakopoulos, S., Touloumi, G., Vourli, G., Raptopoulou-Gigi, M., Vafiadis-Zoumbouli, I., Vasiliadis, T., Mimidis, K., Gogos, C., Ketikoglou, I., et al. (2011) · Gut · doi:10.1136/gut.2010.221846 · Cited by 186
Self-citationAccuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment
Wong, G. L., Chan, H. L., Chan, H., Tse, P. C., Tse, Y., Mak, C. W., Lee, S. K., Ip, Z. M., Lam, A. T., Iu, H. W., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.002 · Cited by 172
Papatheodoridis, G. V., Dalekos, G. N., Yurdaydin, C., Buti, M., Goulis, J., Arends, P., Sypsa, V., Manolakopoulos, S., Mangia, G., Gatselis, N., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.045 · Cited by 158
Self-citationKumada, T., Toyoda, H., Tada, T., Kiriyama, S., Tanikawa, M., Hisanaga, Y., Kanamori, A., Niinomi, T., Yasuda, S., Andou, Y., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.025 · Cited by 142
Non-invasive assessment of liver fibrosis: are we ready?
Castéra, L., & Pinzani, M. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62195-4 · Cited by 123
Optimal management of hepatitis B virus infection – EASL Special Conference
Lampertico, P., Maini, M. K., & Papatheodoridis, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.026 · Cited by 108
Self-citationChen, Y. C., Peng, C., Jeng, W., Chien, R., & Liaw, Y. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13409 · Cited by 55
Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy
Vlachogiannakos, J. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i47.8822 · Cited by 46
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & El‐Serag, H. B. (2021) · Hepatology · doi:10.1002/hep.31288 · Cited by 2,147
Epidemiology and Management of Hepatocellular Carcinoma
Kulik, L., & El-Serag, H. B. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.08.065 · Cited by 1,735
Metadata
- Authors
- Papatheodoridis, G. V., Idilman, R., Dalekos, G. N., Buti, M., Chi, H., van Boemmel, F., Calleja, J. L., Sypsa, V., Goulis, J., Manolakopoulos, S., Loglio, A., Siakavellas, S., Keskın, O., Gatselis, N., Hansen, B. E., Lehretz, M., de la Revilla, J., Savvidou, S., Kourikou, A., Vlachogiannakos, I., Galanis, K., Yurdaydin, C., Berg, T., Colombo, M., Esteban, R., Janssen, H. L. A., & Lampertico, P.
- Venue
- Hepatology
- Published
- 2017-10-11
- Volume
- 66
- Issue
- 5
- Pages
- 1444-1453
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2626176186
- Cited by
- 301
- References
- 28
- FWCI
- 26.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.